Presentation
The overall objective of PEVIA is to bring this new pan-Ebola vaccine up to a stage ready for testing in an outbreak setting by comprehensively analyzing their immunological and safety profile in human using cutting-edge technologies. The project, officially kicked off June 1st 2017, also addresses the development innovative functional analysis tools to accelerate the development of new vaccine candidates against Ebola virus and Filovirus as well as novel diagnostic tests that can be readily deployed in the field. PEVIA project will have a significant impact on global health, both at the individual and the public health levels, and will increase the readiness to respond to future outbreaks of Ebola and other filoviral haemorrhagic.
PEVIA is a public-private consortium made up of 13 partners involving 3 small and medium enterprises (SMEs), and experts from 10 academic institutions, including scientists of two BSL-4 laboratories and four clinical centers (France, Switzerland, Benin, Tanzania).
PEVIA is a 6 years project started in June 2017 and funded by the Innovative Medicine Initiative 2 Joint Undertaking (IMI 2 JU).
Project duration
6 years
|
Funding
6.2 millions €
|
Number of partners
13
|
Starting date
June 01, 2017
|
Coordinator : AP-HP/CIC
Joliot institute contacts:
Bernard Maillère (bernard.maillere@cea.fr) et Laurent Bellanger (laurent.bellanger@cea.fr)
website :
pevia-ebola.eu/
H2020 agreement id : 116088
ABOUT IMI - INNOVATIVE MEDICINES INITIATIVE
IMI is the world's largest public-private partnership (PPP) in the life sciences. It is a partnership between the European Union (represented by the European Commission) and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations).
The objective of IMI, particularly in its second phase (IMI2, 2014-2020), is to develop new generation vaccines, drugs and treatments, such as new antibiotics.
For more information: https://www.imi.europa.eu/